Aceragen, Inc. (ACGN) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Exton, PA, 美国. 现任CEO为 John C. Taylor.
ACGN 拥有 IPO日期为 1996-01-25, 26 名全职员工, 在 NASDAQ Capital Marke, 市值为 $3.24M.
Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States. Its clinical development pipeline includes ACG-701, which is in Phase 2 clinical trial for cystic fibrosis pulmonary exacerbations, as well as for melioidosis; and ACG-801 for farber disease. Aceragen, Inc. has a collaboration and option agreement with Scriptr Global, Inc. to identify, research, and develop gene therapy candidates for the treatment, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich's Ataxia. The company was formerly known as Idera Pharmaceuticals, Inc. and changed its name to Aceragen, Inc. in January 2023. Aceragen, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.
